US Patent Issued to National University of Singapore on Sept. 15 for "Engineered dysbiosis-sensing probiotic for clostridium difficile infections and recurring infections management" (Singaporean Inventors)

ALEXANDRIA, Va., Sept. 15 -- United States Patent no. 12,735,714, issued on Sept. 15, was assigned to National University of Singapore (Singapore).

"Engineered dysbiosis-sensing probiotic for clostridium difficile infections and recurring infections management" was invented by Elvin Koh (Singapore), In Young Hwang (Singapore) and Matthew Wook Chang (Singapore).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to methods of metabolic engineering bacteria cells to produce bile salt hydrolase to inhibit the germination of C. difficile endospores and colonisation within the human gastrointestinal tract. The bile salt hydrolase is operably linked to a sialic acid-inducible promoter, pNan...